Vorapaxar and optimal aspirin dose: The FDA outlook

Abstract Vorapaxar, a novel thrombin PAR-1 inhibitor, approved for post-myocardial infarction, and peripheral artery disease indications has been tested in 2 major clinical trials. In the successful TRA2P, antecedent aspirin (ASA) has been used in 94% of patients, and in failed TRACER in over 96% of...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cardiology Vol. 203; pp. 903 - 905
Main Authors:	Serebruany, Victor L, Fortmann, Seth D, Kim, Moo Hyun
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ireland Ltd 15-01-2016
Subjects:	Aspirin Aspirin - administration & dosage Bleeding Cardiovascular Clinical trials Drug Approval - methods Efficacy Humans Lactones - administration & dosage Platelet Aggregation Inhibitors - administration & dosage Pyridines - administration & dosage Receptors, Thrombin - antagonists & inhibitors United States United States Food and Drug Administration Vorapaxar Clinical trials Efficacy Aspirin Vorapaxar Bleeding
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!